New technology reduces the profitability for new drugs
نویسندگان
چکیده
منابع مشابه
NEW DRUGS NEW DRUGS Ferriprox Reduces Excess Iron
NEW DRUGS Ferriprox Reduces Excess Iron Deferiprone (Ferriprox, Apo-Pharma, Inc.) has been approved to treat iron overload resulting from blood transfusions in patients with thalassemia who have responded inadequately to previous chelation therapy. Thalassemia is a genetic blood disorder that causes anemia. Patients with thalassemia have excess iron levels from frequent blood transfusions, a se...
متن کاملa new approach to credibility premium for zero-inflated poisson models for panel data
هدف اصلی از این تحقیق به دست آوردن و مقایسه حق بیمه باورمندی در مدل های شمارشی گزارش نشده برای داده های طولی می باشد. در این تحقیق حق بیمه های پبش گویی بر اساس توابع ضرر مربع خطا و نمایی محاسبه شده و با هم مقایسه می شود. تمایل به گرفتن پاداش و جایزه یکی از دلایل مهم برای گزارش ندادن تصادفات می باشد و افراد برای استفاده از تخفیف اغلب از گزارش تصادفات با هزینه پائین خودداری می کنند، در این تحقیق ...
15 صفحه اولnew semigroup compactifications via the enveloping semigroups of associated flows
this thesis deals with the construction of some function algebras whose corresponding semigroup compactification are universal with respect to some properies of their enveloping semigroups. the special properties are of beigan a left zero, a left simple, a group, an inflation of the right zero, and an inflation of the rectangular band.
15 صفحه اولIslamic and Iranian traditional materia medica works as the treasure for finding new effective drugs
The Materia Medica works of Rhazes, (vol2 of Canon), Al-Biruni (Kitab as -Saidana), Abu Mansur (Haqaiq al-Adwiya), Gorgani (Vol 9 and 10 of Zahira-e-Harazmsahi), Ansari Shirazi (Ihtiyarat-e-Bdi i), Hakim Mu min (Tuhfa) and Aqili Hurasani (Aqrabuzin-e Kabir) and others are the most important works of Islamic and Iranian physicians on Natural Drugs. The systematic pharmacognostical, pharmacologic...
متن کاملNEW DRUGS NEW DRUGS Efalizumab for Plaque Psoriasis
NEW DRUGS Efalizumab for Plaque Psoriasis Genentech, Inc., and Xoma, Ltd., have announced the approval of efalizumab (RaptivaTM) by the U.S. Food and Drug Administration (FDA) for the treatment of chronic, moderate-to-severe plaque psoriasis in adults age 18 or older who are candidates for systemic therapy or phototherapy. This is the first biological agent that is designed to provide continuou...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Genome Biology
سال: 2001
ISSN: 1465-6906
DOI: 10.1186/gb-spotlight-20010412-03